Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, MN; Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH.
Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH.
Am J Transplant. 2024 Feb;24(2S1):S394-S456. doi: 10.1016/j.ajt.2024.01.017.
For the first time since the COVID-19 pandemic, the annual number of lung transplants performed in the United States increased. The year 2022, encompassed in this report, marks the last full calendar year where the Lung Allocation Score was used for ranking transplant candidates based on their estimated transplant benefit and donor lung allocation in the United States. In March 2023, a major change in transplant allocation policy occurred with the implementation of the Composite Allocation Score. Transplant rates have increased over the past decade, although there is variability among age, diagnosis, racial and ethnic, and blood groups. Over half of candidates received a lung transplant within 3 months of placement on the waiting list, with nearly 75% of candidates accessing transplant by 1 year. Pretransplant mortality rates remained stable, with approximately 13% of lung transplant candidates dying or being removed from the waiting list within a year of listing. Posttransplant survival remained stable; however, variability exists by age, diagnosis, and racial and ethnic groups.
自 COVID-19 大流行以来,美国每年进行的肺移植数量首次增加。本报告涵盖的 2022 年标志着最后一个完整的历年,在美国,肺分配评分(Lung Allocation Score)被用于根据移植候选人的预计移植获益和供肺分配对其进行排名。2023 年 3 月,随着综合分配评分(Composite Allocation Score)的实施,移植分配政策发生了重大变化。在过去的十年中,移植率有所增加,尽管在年龄、诊断、种族和民族以及血型方面存在差异。超过一半的候选人在等待名单上登记后 3 个月内接受了肺移植,近 75%的候选人在 1 年内获得了移植。移植前死亡率保持稳定,大约 13%的肺移植候选人在登记后 1 年内死亡或从等待名单中除名。移植后生存率保持稳定;然而,在年龄、诊断和种族和民族群体方面存在差异。